Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers
- PMID: 22954966
- PMCID: PMC3457786
- DOI: 10.1016/j.jchromb.2012.08.011
Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers
Abstract
In the current study, we developed a HPLC method to quantitatively measure the permeability of the BpT-based chelators, 2-benzoylpyridine 4-ethyl-3-thiosemicarbazone (Bp4eT) and 2-benzoylpyridine 4-allyl-3-thiosemicarbazone (Bp4aT), across human colorectal adenocarcinoma (Caco-2) monolayers as a model of gut absorption. In aqueous solution, Bp4eT and Bp4aT formed inter-convertible Z and E isomers that were resolved by HPLC. Peak area was linear with respect to chelator concentration. Acceptable within-day and between-day precision (<22%) and accuracy (85-115% of true values) were obtained over a range of 1.0-100μM for Bp4eT and 1.5-300μM for Bp4aT. Limits of detection were 0.3μM and 1μM for Bp4eT and Bp4aT, respectively, while corresponding limits of quantification were 1μM and 5μM. Both chelators showed significant ability to chelate iron in THP-1 cells using a calcein-based assay and no apparent cytotoxicity was observed within 24h. Ratios of the apical to basolateral and basolateral to apical transport for Bp4eT were 1.10 and 0.89 at 100μM and 300μM respectively, indicating equal bi-directional movement of the compounds. Similarly, ratios were 0.77 and 0.92 for Bp4aT, respectively. This study demonstrates that Bp4eT and Bp4aT can be efficiently transported through Caco-2 cells and can potentially be formulated for oral delivery.
Copyright © 2012 Elsevier B.V. All rights reserved.
Figures





Similar articles
-
In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites.PLoS One. 2015 Oct 13;10(10):e0139929. doi: 10.1371/journal.pone.0139929. eCollection 2015. PLoS One. 2015. PMID: 26460540 Free PMC article.
-
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9.Mol Pharmacol. 2011 Jan;79(1):185-96. doi: 10.1124/mol.110.069062. Epub 2010 Oct 18. Mol Pharmacol. 2011. PMID: 20956357 Free PMC article.
-
Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer.Mol Pharmacol. 2010 Oct;78(4):675-84. doi: 10.1124/mol.110.066126. Epub 2010 Jul 6. Mol Pharmacol. 2010. PMID: 20605952
-
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.J Med Chem. 2009 Sep 10;52(17):5271-94. doi: 10.1021/jm900552r. J Med Chem. 2009. PMID: 19601577 Review. No abstract available.
-
Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity.Curr Drug Deliv. 2010 Jul;7(3):194-207. doi: 10.2174/156720110791560991. Curr Drug Deliv. 2010. PMID: 20507267 Review.
Cited by
-
Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase IκB-α expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription.Antimicrob Agents Chemother. 2014 Nov;58(11):6558-71. doi: 10.1128/AAC.02918-14. Epub 2014 Aug 25. Antimicrob Agents Chemother. 2014. PMID: 25155598 Free PMC article.
-
Synthesis and Antibacterial Activity of Novel Hydroxy Semicarbazone Derivatives.Iran J Pharm Res. 2016 Winter;15(Suppl):29-35. Iran J Pharm Res. 2016. PMID: 28228801 Free PMC article.
-
In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites.PLoS One. 2015 Oct 13;10(10):e0139929. doi: 10.1371/journal.pone.0139929. eCollection 2015. PLoS One. 2015. PMID: 26460540 Free PMC article.
-
A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate--ZMC1.Biomed Chromatogr. 2015 Nov;29(11):1708-14. doi: 10.1002/bmc.3483. Epub 2015 May 5. Biomed Chromatogr. 2015. PMID: 25944179 Free PMC article.
References
-
- Pandeya SN, Sriram D, Nath G, DeClercq E. Eur J Pharm Sci. 1999;9:25. - PubMed
-
- Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV, Richardson DR. J Med Chem. 2009;52:5271. - PubMed
-
- Jansson PJ, Sharpe PC, Bernhardt PV, Richardson DR. J Med Chem. 2010;53:5759. - PubMed
-
- Kalinowski DS, Yu Y, Sharpe PC, Islam M, Liao YT, Lovejoy DB, Kumar N, Bernhardt PV, Richardson DR. J Med Chem. 2007;50:3716. - PubMed
-
- de Monye C, Karcher DS, Boelaert JR, Gordeuk VR. AIDS. 1999;13:375. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- KL2RR031974/RR/NCRR NIH HHS/United States
- F31 HL090025/HL/NHLBI NIH HHS/United States
- UL1 RR031975/RR/NCRR NIH HHS/United States
- 2R25 HL003679-08/HL/NHLBI NIH HHS/United States
- UL1RR031975/RR/NCRR NIH HHS/United States
- 2MO1 RR10284/RR/NCRR NIH HHS/United States
- SC3 GM083752/GM/NIGMS NIH HHS/United States
- R25 HL003679/HL/NHLBI NIH HHS/United States
- 1SC3GM083752/GM/NIGMS NIH HHS/United States
- M01 RR010284/RR/NCRR NIH HHS/United States
- KL2 RR031974/RR/NCRR NIH HHS/United States
- 1SC1GM082325/GM/NIGMS NIH HHS/United States
- 2G12RR003048/RR/NCRR NIH HHS/United States
- SC1 GM082325/GM/NIGMS NIH HHS/United States
- G12 RR003048/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources